Skip to main content

Jorge E Lascano, MD

Critical Care Specialist

Photo of Jorge E Lascano

Research at a glance

Top areas of exploration

  • alpha 1-Antitrypsin Deficiency , 11 publications
  • Pulmonary Disease, Chronic Obstructive , 9 publications
  • alpha 1-Antitrypsin , 8 publications
  • Lung , 4 publications

Research activity

48 publications

634 citations

Why is this important?

Active clinical trials

KRYS-LTFU-01
Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
Adults
REACH-OB-23

The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not…

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
Both
Sexes
All
Serpentine-1

The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency…

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
Adults
Sexes
All

My publications

48 publications

2026

Polymerized Z-α-1 antitrypsin leads to lung injury in a murine model of emphysema.

JCI insight

PubMed • Publisher's site

2026

Epidemiology of Alpha-1 Antitrypsin Deficiency in the Veterans Health Administration.

Annals of the American Thoracic Society

PubMed • Publisher's site

2026

Cardiovascular disease-associated admissions in patients with Cystic Fibrosis: A 7-Year U.S. National Inpatient Sample Analysis.

Heart & lung : the journal of critical care

PubMed • Publisher's site

2025

Inhaled alpha-1 antitrypsin (AAT) restores lower respiratory tract protease-antiprotease homoeostasis and reduces inflammation in AAT-deficient individuals: a randomised phase 2 study.

ERJ open research

PubMed • Publisher's site